Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy

Background: Ixekizumab, an interleukin-17A (IL-17A) inhibitor used in psoriasis treatment, has been linked to drug-induced interstitial lung disease (DI-ILD). The pathophysiological mechanisms and histopathological features of this adverse effect remain poorly documented.Case Presentation: A 69-year...

Cijeli opis

Bibliografski detalji

Glavni autori:	Shota Kaburaki, Naoko Okada, Toru Tanaka, Koichiro Kamio, Yosuke Tanaka, Yasuhiro Terasaki, Kazuo Kasahara, Masahiro Seike
Format:	Artigo
Jezik:	Inglês
Izdano:	Taylor & Francis Group 2024-12-01
Serija:	Journal of Dermatological Treatment
Teme:	Transbronchial lung cryobiopsy drug-induced interstitial lung disease ixekizumab psoriasis
Online pristup:	https://www.tandfonline.com/doi/10.1080/09546634.2024.2424338
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!